What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
What 13 Analyst Ratings Have To Say About Halozyme Therapeutics
關於奧洛茲美醫療的13位分析師評級報告
Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
在過去三個月中，13位分析師對Halozyme Therapeutics（納斯達克股票代碼：HALO）進行了分析，揭示了從看漲到看跌的不同觀點。
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
下表總結了他們最近的評估，說明了過去30天不斷變化的情緒，並將其與前幾個月進行了比較。
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $57.69, a high estimate of $71.00, and a low estimate of $50.00. This upward trend is evident, with the current average reflecting a 3.52% increase from the previous average price target of $55.73.
分析師評估的12個月目標股價揭示了進一步的見解，平均目標價爲57.69美元，最高估計爲71.00美元，低估值爲50.00美元。這種上升趨勢顯而易見，當前的平均價格較之前的55.73美元的平均目標股價上漲了3.52％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析師評級：詳細審查
A comprehensive examination of...
對金融專...
登入免費觀看全文
登入/註冊